Mechanisms of anti-ischemic action of prostaglandin E1 in peripheral arterial occlusive disease

Vasa - Journal of Vascular Diseases

Volumn 33, Issue 3, 2004, Pages 119-124

  Schrör, Karsten ^a   Hohlfeld, T ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Mechanism of action; Peripheral arterial disease; Prostaglandin E1

Indexed keywords

CELL ADHESION MOLECULE; COLLAGEN TYPE 1; CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE RICH PROTEIN 61; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GROWTH FACTOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; BLOOD FLOW; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FIBRINOLYSIS; FIBROBLAST; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; LEG ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; SMOOTH MUSCLE FIBER; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE; VISCOSITY;

EID: 4344574427     PISSN: 03011526     EISSN: None     Source Type: Journal    
DOI: 10.1024/0301-1526.33.3.119     Document Type: Review

References (30)

1. Barradas M, Stansby G, Hamilton G, Mikhailidis DP. Effect of naftidrofuryl and aspirin on platelet aggregation in peripheral vascular disease. In Vivo 1993; 7: 543-8.
2. Belch JJF, Bell PRF, Creissen D, Dormandy JA. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication. Circulation 1997; 95: 2298-302.
3. Belton O, Byrne D, Kearney D, Leahy A, FitzGerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000; 102: 840-5.
4. Brevetti G, Martone VD, de Cristofaro T, Corrado S, Silvestro A, Di Donato AM, Bucur R, Scopacasa F. High levels of adhesion molecules are associated with impaired endothelium-dependent vasodilation in patients with peripheral arterial disease. Thromb Haemost 2001; 85: 63-6.
5. Creutzig A, Lehmacher W, Elze M. Meta-analysis of randomised controlled prostaglandin E1 studies in peripheral arterial occlusive disease stages III and IV. VASA 2004; 35: 137-144.
6. Davi G, Gresele P, Violi F, Basili St, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96: 69-75.
7. Debey S, Kirchrath L, Schrör K, Meyer-Kirchrath J. Iloprost down-regulates the expression of the growth regulatory gene Cyr61 in human vascular smooth muscle cells. Eur J Pharmacol 2003; 474: 161-4.
8. Debey S, Meyer-Kirchrath J, Schrör K. Regulation of cyclooxygenase-2 expression by iloprost in human vascular smooth muscle cells. Role of transcription factors CREB and ICER. Biochem Pharmacol 2003; 65: 979-88.
9. Diehm C. Aspirin resistance in peripheral arterial disease. In: Schrör K (ed.) Aspirin-"Resistance" or "Non- Responsiveness". Frechen: Dr. Schrör Verlag 2004: 87-96.
10. 1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial. J Vasc Surg 1997; 25: 537-44.
11. 1 reduces soluble vascular cell adhesion molecule-1 in peripheral arterial obstructive disease. Am Heart J 2001; 142: 733-9.
12. Gordon D, Bray MA, Morley J. Control of lymphokine secretion by prostaglandins. Nature (Lond.) 1976; 262: 401-2.
13. 2. Naunyn-Schmiedeberg's Arch Pharmacol 1990; 341: 308-15.
14. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001; 344: 1608-21.
15. 2 downregulates interleukin-12 production through EP4 receptors in human monocytes stimulated with lipopolysaccharide from actinobacillus actinomycetecomitans and interferon-gamma. Oral Microbiol Immunol 2003; 18: 150-5.
16. Koksch M, Zeiger F, Wittig K, Siegemund A, Reininger CB, Pfeiffer D, Ruehlmann C. Coagulation, fibrinolysis and platelet P-selectin expression in peripheral vascular disease. Eur J Vasc Endovasc Surg 2001; 21: 147-54.
17. 1 on plasma endothelin-1 release in patients with intermittent claudication. Int J Clin Pharmacol Ther 1999; 37: 347-51.
18. 1 improves endothelial function in critical limb ischemia. J Cardiovasc Pharmacol 2003; 41: 249-53.
19. Matsagas MI, Geroulakos G, Mikhailidis DP, Pasth FRC. The role of platelets in peripheral arterial disease: therapeutic implications. Ann Vasc Surg 2002; 16: 246-58.
20. 1 reduces monocyte chemoattractant protein-1 levels in peripheral arterial obstructive disease. Am Heart J 2003; 145: 330-3.
21. Meyer-Kirchrath J, Debey S, Glandorff C, Kirchrath L, Schrör K. Gene expression profile of the Gs-coupled prostacyclin receptor in human vascular smooth muscle cells. Biochem Pharmacol 2004; 67: 757-65.
22. 1 therapy reduced circulating adhesion molecules (ICAM-1, E-selectin, VCAM-1 in peripheral vascular disease. VASA 2000; 29: 179-85.
23. Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiberer L. Increased platelet and coagulatory activity indicate ongoing thrombogenesis in peripheral arterial disease. Thromb Res 1996; 82: 523-32.
24. Riquet F-B, Lai W-F, Birkhead J-R, Suen L-F, Karsenty G, Goldring M-B. Suppression of type I collagen gene expression by prostaglandins in fibroblasts is mediated at the transcriptional level. Mol Med 2000; 6: 705-19.
25. Scheerer K. Adhäsionsmoleküle auf glatten Gefaß muskelzellen - Bedeutung für die Adhäsion von Monozyten und ihre Beeinflussung durch vasodilatierende Prostaglandine. Inauguraldissertation Düsseldorf 2004.
26. Stratton R, Shiwen X, Martini G, Holmes A, Leask A, Haberberger T, Martin GR, Black CM, Abraham D. Iloprost suppresses connective tissue growth factor production in fibroblasts and in the skin of scleroderma patients. J Clin Invest 2001; 108: 241-50.
27. Sussmann M, Sarbia M, Meyer-Kirchrath J, Nüsing RM, Schrör K, Fischer JW. Induction of hyaluronic acid synthase 2 (HAS2) in human vascular smooth muscle cells by vasodilatory prostaglandins. Circ Res 2004; 94: 592-600.
28. Upchurch GJ, Ramdev N, Walsh M, Loscalzo J. Prothrombotic consequences of the oxidation of fibrinogen and their inhibition by aspirin. J Thromb Thrombolysis 1998; 5: 9-14.
29. 1. Prostaglandins Leukot Ess Fatty Acids 2000; 63: 271-7.
30. 1. Prostaglandins Leukot Ess Fatty Acids 2002; 67: 277-81.